These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22503023)

  • 1. Intermittent androgen suppression--ready for prime time?
    Ischia J; Goldenberg SL
    J Urol; 2012 Jun; 187(6):1956-7. PubMed ID: 22503023
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment.
    Mearini L
    J Urol; 2012 Jun; 187(6):2166-7. PubMed ID: 22503017
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
    Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
    J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy.
    Teruel JL; Cano T; Marcén R; Villafruela JJ; Rivera M; Fernández-Juarez G; Ortuño J
    Nephrol Dial Transplant; 1997 Jun; 12(6):1262-3. PubMed ID: 9198065
    [No Abstract]   [Full Text] [Related]  

  • 7. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
    Egawa S; Takashima R; Matsumoto K; Mizoguchi H; Kuwao S; Baba S
    Jpn J Clin Oncol; 2000 Jan; 30(1):21-6. PubMed ID: 10770564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
    Lin CJ; Hsieh RK; Lim KH; Chen HH; Cheng YC; Wu CJ
    South Med J; 2007 Sep; 100(9):916-7. PubMed ID: 17902299
    [No Abstract]   [Full Text] [Related]  

  • 10. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Crawford ED
    Urology; 1995 Dec; 46(6):899-901. PubMed ID: 7502440
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
    Têtu B
    Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
    [No Abstract]   [Full Text] [Related]  

  • 12. Response of carcinoma of the prostate to withdrawal of flutamide.
    Collinson MP; Daniel F; Tyrrell CJ; Teasdale C
    Br J Urol; 1993 Nov; 72(5 Pt 1):662-3. PubMed ID: 10071562
    [No Abstract]   [Full Text] [Related]  

  • 13. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?
    Mottet N
    Eur Urol; 2013 Jan; 63(1):121-2; discussion 123-4. PubMed ID: 22921963
    [No Abstract]   [Full Text] [Related]  

  • 14. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
    Mottet N; Lucas C; Sene E; Avances C; Maubach L; Wolff JM
    Urol Int; 2005; 75(3):204-8. PubMed ID: 16215305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histological investigation of prostate cancer treated with hormonal agents].
    Azumi M; Saga Y; Hashimoto H; Kakizaki H
    Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
    Figg WD; Dawson N; Middleman MN; Brawley O; Lush RM; Senderowicz A; Steinberg SH; Tompkins A; Reed E; Sartor O
    Acta Oncol; 1996; 35(6):763-5. PubMed ID: 8938230
    [No Abstract]   [Full Text] [Related]  

  • 17. [The question of intermittent hormonal treatment of cancer of the prostate].
    Boca P
    Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
    Bono AV; DiSilverio F; Robustelli della Cuna G; Benvenuti C; Brausi M; Ferrari P; Gibba A; Galli L
    Urol Int; 1998; 60 Suppl 1():18-24. PubMed ID: 9563140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.
    Higano CS; Ellis W; Russell K; Lange PH
    Urology; 1996 Nov; 48(5):800-4. PubMed ID: 8911533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study.
    Spry NA; Taaffe DR; England PJ; Judge JS; Stephens DA; Peddle-McIntyre C; Baker MK; Newton RU; Galvão DA
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):67-72. PubMed ID: 22907511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.